Paroxysmal supraventricular tachycardia: Experience with propafenone

V. Santinelli, M. De Paola, P. Turco, D. Smimmo, M. Chiariello

Research output: Contribution to journalArticle

Abstract

The authors studied the efficacy of intravenous (IV) (1.5-2 mg/kg) and oral propafenone (450 to 900 mg/day) in 16 patients with paroxysmal, sustained, recurrent supraventricular tachycardia (SVT). In 5 patients IV propafenone was not given, because of intolerant SVT. Nine patients had Wolff-Parkinson-White syndrome. IV propafenone immediately stopped and prevented reinduction of SVT in 9/11 patients. Oral propafenone prevented SVT induction in 3 of 5 patients. In the 9 patients responsive to IV propafenone, oral propafenone was effective: in particular, in 6 patients SVT tachycardia was not induced by serial transesophageal pacings, and in the remaining 3 patients the arrhythmia was still induced but was slower and of brief duration (3-5 seconds). In 11/12 patients responsive to oral propafenone the minimum effective dosage in preventing the induction of the arrhythmia was 600 mg/day. In only 1 patient was the dose of 450 mg/day equally effective. Propafenone administration was not associated with major side effects. In conclusion, propafenone is very effective in the control of paroxysmal supraventricular tachycardia; intravenous propafenone can predict the efficacy of oral therapy.

Original languageEnglish
Pages (from-to)563-568
Number of pages6
JournalAngiology
Volume40
Issue number6
Publication statusPublished - 1989

Fingerprint

Propafenone
Paroxysmal Tachycardia
Supraventricular Tachycardia
Cardiac Arrhythmias
Wolff-Parkinson-White Syndrome
Tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Santinelli, V., De Paola, M., Turco, P., Smimmo, D., & Chiariello, M. (1989). Paroxysmal supraventricular tachycardia: Experience with propafenone. Angiology, 40(6), 563-568.

Paroxysmal supraventricular tachycardia : Experience with propafenone. / Santinelli, V.; De Paola, M.; Turco, P.; Smimmo, D.; Chiariello, M.

In: Angiology, Vol. 40, No. 6, 1989, p. 563-568.

Research output: Contribution to journalArticle

Santinelli, V, De Paola, M, Turco, P, Smimmo, D & Chiariello, M 1989, 'Paroxysmal supraventricular tachycardia: Experience with propafenone', Angiology, vol. 40, no. 6, pp. 563-568.
Santinelli V, De Paola M, Turco P, Smimmo D, Chiariello M. Paroxysmal supraventricular tachycardia: Experience with propafenone. Angiology. 1989;40(6):563-568.
Santinelli, V. ; De Paola, M. ; Turco, P. ; Smimmo, D. ; Chiariello, M. / Paroxysmal supraventricular tachycardia : Experience with propafenone. In: Angiology. 1989 ; Vol. 40, No. 6. pp. 563-568.
@article{55218be4ae884c959841d773f2c13c09,
title = "Paroxysmal supraventricular tachycardia: Experience with propafenone",
abstract = "The authors studied the efficacy of intravenous (IV) (1.5-2 mg/kg) and oral propafenone (450 to 900 mg/day) in 16 patients with paroxysmal, sustained, recurrent supraventricular tachycardia (SVT). In 5 patients IV propafenone was not given, because of intolerant SVT. Nine patients had Wolff-Parkinson-White syndrome. IV propafenone immediately stopped and prevented reinduction of SVT in 9/11 patients. Oral propafenone prevented SVT induction in 3 of 5 patients. In the 9 patients responsive to IV propafenone, oral propafenone was effective: in particular, in 6 patients SVT tachycardia was not induced by serial transesophageal pacings, and in the remaining 3 patients the arrhythmia was still induced but was slower and of brief duration (3-5 seconds). In 11/12 patients responsive to oral propafenone the minimum effective dosage in preventing the induction of the arrhythmia was 600 mg/day. In only 1 patient was the dose of 450 mg/day equally effective. Propafenone administration was not associated with major side effects. In conclusion, propafenone is very effective in the control of paroxysmal supraventricular tachycardia; intravenous propafenone can predict the efficacy of oral therapy.",
author = "V. Santinelli and {De Paola}, M. and P. Turco and D. Smimmo and M. Chiariello",
year = "1989",
language = "English",
volume = "40",
pages = "563--568",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Paroxysmal supraventricular tachycardia

T2 - Experience with propafenone

AU - Santinelli, V.

AU - De Paola, M.

AU - Turco, P.

AU - Smimmo, D.

AU - Chiariello, M.

PY - 1989

Y1 - 1989

N2 - The authors studied the efficacy of intravenous (IV) (1.5-2 mg/kg) and oral propafenone (450 to 900 mg/day) in 16 patients with paroxysmal, sustained, recurrent supraventricular tachycardia (SVT). In 5 patients IV propafenone was not given, because of intolerant SVT. Nine patients had Wolff-Parkinson-White syndrome. IV propafenone immediately stopped and prevented reinduction of SVT in 9/11 patients. Oral propafenone prevented SVT induction in 3 of 5 patients. In the 9 patients responsive to IV propafenone, oral propafenone was effective: in particular, in 6 patients SVT tachycardia was not induced by serial transesophageal pacings, and in the remaining 3 patients the arrhythmia was still induced but was slower and of brief duration (3-5 seconds). In 11/12 patients responsive to oral propafenone the minimum effective dosage in preventing the induction of the arrhythmia was 600 mg/day. In only 1 patient was the dose of 450 mg/day equally effective. Propafenone administration was not associated with major side effects. In conclusion, propafenone is very effective in the control of paroxysmal supraventricular tachycardia; intravenous propafenone can predict the efficacy of oral therapy.

AB - The authors studied the efficacy of intravenous (IV) (1.5-2 mg/kg) and oral propafenone (450 to 900 mg/day) in 16 patients with paroxysmal, sustained, recurrent supraventricular tachycardia (SVT). In 5 patients IV propafenone was not given, because of intolerant SVT. Nine patients had Wolff-Parkinson-White syndrome. IV propafenone immediately stopped and prevented reinduction of SVT in 9/11 patients. Oral propafenone prevented SVT induction in 3 of 5 patients. In the 9 patients responsive to IV propafenone, oral propafenone was effective: in particular, in 6 patients SVT tachycardia was not induced by serial transesophageal pacings, and in the remaining 3 patients the arrhythmia was still induced but was slower and of brief duration (3-5 seconds). In 11/12 patients responsive to oral propafenone the minimum effective dosage in preventing the induction of the arrhythmia was 600 mg/day. In only 1 patient was the dose of 450 mg/day equally effective. Propafenone administration was not associated with major side effects. In conclusion, propafenone is very effective in the control of paroxysmal supraventricular tachycardia; intravenous propafenone can predict the efficacy of oral therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024405903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024405903&partnerID=8YFLogxK

M3 - Article

C2 - 2719341

AN - SCOPUS:0024405903

VL - 40

SP - 563

EP - 568

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 6

ER -